Sarah-Jane Dawson
#68,819
Most Influential Person Now
Australian clinician-scientist
Sarah-Jane Dawson's AcademicInfluence.com Rankings
Sarah-Jane Dawsonphilosophy Degrees
Philosophy
#11712
World Rank
#16178
Historical Rank
Logic
#8509
World Rank
#10665
Historical Rank
Download Badge
Philosophy
Sarah-Jane Dawson's Degrees
- PhD Cancer Biology University of Melbourne
Why Is Sarah-Jane Dawson Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sarah-Jane Dawson is an Australian clinician-scientist. She is a consultant medical oncologist and head of the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre in Melbourne. Her current research interests are focused on the development of noninvasive blood-based biomarkers for clinical application, including early detection, risk stratification and disease monitoring in cancer management.
Sarah-Jane Dawson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Analysis of circulating tumor DNA to monitor metastatic breast cancer. (2013) (1628)
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA (2013) (1472)
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016) (1125)
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA (2012) (1125)
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies (2010) (1025)
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. (2014) (684)
- Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. (2014) (588)
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity (2017) (510)
- BET inhibitor resistance emerges from leukaemia stem cells (2015) (425)
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer (2015) (397)
- Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma (2018) (282)
- A new genome‐driven integrated classification of breast cancer and its implications (2013) (280)
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer (2019) (265)
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (2010) (241)
- Triple negative breast cancers: clinical and prognostic implications. (2009) (233)
- PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. (2015) (232)
- Non-genetic mechanisms of therapeutic resistance in cancer (2020) (201)
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation (2020) (187)
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. (2019) (172)
- Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? (2014) (152)
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. (2017) (144)
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies (2020) (137)
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma (2018) (124)
- Common breast cancer susceptibility loci are associated with triple-negative breast cancer. (2011) (124)
- Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia (2019) (107)
- The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE” (2016) (104)
- Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance (2011) (97)
- Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival (2009) (92)
- Click chemistry enables preclinical evaluation of targeted epigenetic therapies (2017) (90)
- Circulating tumor DNA to monitor metastatic breast cancer. (2013) (86)
- Multi-omic machine learning predictor of breast cancer therapy response (2021) (86)
- The value of cell‐free DNA for molecular pathology (2018) (82)
- Functional interdependence of BRD4 and DOT1L in MLL leukemia (2016) (80)
- A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. (2018) (80)
- Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. (2017) (78)
- A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer (2012) (75)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
- Biological and prognostic associations of miR‐205 and let‐7b in breast cancer revealed by in situ hybridization analysis of micro‐RNA expression in arrays of archival tumour tissue (2012) (74)
- HBO1 is required for the maintenance of leukaemia stem cells (2019) (74)
- Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer (2012) (72)
- Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients (2018) (69)
- Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia (2017) (60)
- Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer (2011) (54)
- A community-based model of rapid autopsy in end-stage cancer patients (2016) (54)
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (2010) (53)
- Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes (2016) (50)
- Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. (2008) (50)
- Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. (2017) (49)
- Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. (2019) (49)
- Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (47)
- HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults (2021) (42)
- Non-genetic determinants of malignant clonal fitness at single-cell resolution (2021) (42)
- Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. (2019) (40)
- Severe hypoglycaemia after long‐acting octreotide in a patient with an unrecognized malignant insulinoma (2007) (39)
- Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation (2008) (38)
- Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors (2020) (35)
- Astronomical algorithms for automated analysis of tissue protein expression in breast cancer (2013) (35)
- A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer (2006) (33)
- Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy (2020) (28)
- Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling (2021) (27)
- Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing. (2020) (24)
- Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late (2021) (23)
- Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium (2014) (23)
- Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study (2019) (23)
- Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression (2013) (21)
- Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2020) (19)
- The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. (2016) (19)
- Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. (2008) (18)
- Detection of cell-free microbial DNA using a contaminant-controlled analysis framework (2021) (13)
- Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study (2020) (12)
- Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death (2021) (11)
- Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays (2016) (9)
- Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study. (2017) (9)
- Characterizing the Cancer Genome in Blood. (2018) (8)
- Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study. (2017) (7)
- Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology? (2017) (7)
- Loss of Heterozygosity at the BRCA 2 Locus Detected byMultiplex Ligation-Dependent ProbeAmplification is Common in Prostate Cancers fromMenwith a Germline BRCA 2 Mutation (2008) (6)
- Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE" (2017) (6)
- COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY (2017) (6)
- Combining liquid biopsies and PET-CT for early cancer detection (2020) (5)
- Liquid biopsies for residual disease and recurrence. (2021) (5)
- Cerebral metastases in breast cancer (2005) (5)
- Trastuzumab (T) and CNS metastases in women with HER-2 positive metastatic breast cancer (MBC) (2005) (5)
- Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial (2019) (4)
- Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC) (2019) (4)
- The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent). (2018) (4)
- Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma (2006) (4)
- Images in clinical medicine. Cerebral metastases in breast cancer. (2005) (3)
- Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC). (2018) (3)
- Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. (2016) (3)
- Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab). (2006) (3)
- Large B-cell lymphoma: is the future written in the blood? (2015) (3)
- Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data (2013) (3)
- Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma (2021) (3)
- Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium: Automated scoring of breast tumor TMAs (2014) (2)
- P2.03-044 OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC (2017) (2)
- Central nervous system metastases in women with HER‐2 positive metastatic breast cancer after treatment with trastuzumab (2006) (2)
- Denosumab and invasive cervical root resorption: a case report. (2022) (2)
- 91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial (2022) (2)
- Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer. (2018) (2)
- Non-genetic determinants of malignant clonal fitness at single-cell resolution (2021) (2)
- Bismuth subsalicylate and montmorillonite prevent bile-acid-induced colonic secretion in the rat (1988) (2)
- Targeted Deep Sequencing of Plasma DNA Noninvasive Identification and Monitoring of Cancer Mutations by (2012) (2)
- Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study. (2022) (2)
- Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation (2022) (2)
- Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study (2020) (1)
- Circulating tumor DNA (ctDNA) to track responses and to capture the genomic heterogeneity of metastatic melanoma. (2016) (1)
- Abstract ES8-1: Liquid biopsies in breast cancer - challenges and opportunities (2018) (1)
- Heritable DNA methylation marks associated with susceptibility to breast cancer (2018) (1)
- Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes (2022) (1)
- Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial (2018) (1)
- P76.64 Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE) (2021) (1)
- Abstract OT-27-01: PALVEN: A phase 1b study of palbociclib, letrozole and venetoclax in estrogen receptor, BCL2-positive metastatic breast cancer (2021) (1)
- Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. (2022) (1)
- HBO1 is required for the maintenance of leukaemia stem cells (2019) (1)
- Detection of cell-free microbial DNA using a contaminant-controlled analysis framework (2021) (1)
- Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology (2019) (1)
- Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma. (2018) (1)
- Monitoring of Metastatic Breast Cancer Using Circulating Tumour DNA: A Comparison With Circulating Tumour Cells (2012) (1)
- Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia (2019) (1)
- Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2020) (1)
- Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax (2021) (0)
- Abstract P1-18-14: Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study (2022) (0)
- Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- Abstract IA14: Liquid biopsies for tracking molecular resistance in cancer (2020) (0)
- Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis (2016) (0)
- CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (0)
- Longitudinal Genomic Characterization Using Cell-Free DNA in Patients with Idiopathic Aplastic Anemia (2020) (0)
- Abstract 539: Utility of circulating tumor DNA in esophageal cancer: A potential prognostic biomarker in tumor staging, monitoring of treatment response and detection of recurrent disease (2021) (0)
- Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2022) (0)
- Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy (2018) (0)
- PS02.195: CIRCULATING TUMOUR DNA HAS UTILITY IN THE CLINICAL MANAGEMENT OF ESOPHAGEAL CANCER (2018) (0)
- Running title : CTCs and staging in MBC (2018) (0)
- 1670P Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial) (2022) (0)
- 3122 – SUMOYLATION OF DNMT1 REGULATES RESPONSE TO CATALYTIC INHIBITION OF DNMT1 IN ACUTE MYELOID LEUKAEMIA (2022) (0)
- Identifying changes in mutational dynamics in patients with early breast cancer undergoing neoadjuvant chemotherapy (2016) (0)
- Abstract P5-02-16: SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2- breast cancer (2023) (0)
- A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival (2023) (0)
- Clinical Implications and Biomarkers of Clonal Evolution (2018) (0)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
- Abstract B017: A targeted sequencing approach to characterize the mutational profiles of 178 genes in 2600 primary breast tumors (2013) (0)
- A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study (2023) (0)
- O-19 Comparison of imputation methods for missing immunohistochemical markers in a study of breast cancer prognosis (2010) (0)
- The impact of coding germline variants on contralateral breast cancer risk and survival (2023) (0)
- Abstract 476: Predicting response to treatment in early breast cancer using dynamic integrative multi-omic profiling (2022) (0)
- Forshew 1..12 (2019) (0)
- Clinical translation of somatic mutation analysis of cell-free dna (2015) (0)
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma (2018) (0)
- Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA. (2022) (0)
- Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2022) (0)
- Combining liquid biopsies and PET-CT for early cancer detection (2020) (0)
- Loss of heterozygosity at the BRCA2 locus is a common finding in prostate cancer in men with a germline BRCA2 mutation (2007) (0)
- Custom workflows to improve joint variant calling from multiple related tumour samples: FreeBayesSomatic and Strelka2Pass (2021) (0)
- Globalization, Climate Change, and Human Health (2013) (0)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
- 876 Non-invasive Monitoring of Metastatic Breast Cancer by Circulating Tumour DNA – a Comparison With Circulating Tumour Cells (2012) (0)
- Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- Circulating Tumor DNA in HER2-Ampli fi ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (0)
This paper list is powered by the following services:
Other Resources About Sarah-Jane Dawson
What Schools Are Affiliated With Sarah-Jane Dawson?
Sarah-Jane Dawson is affiliated with the following schools:
